The global precision medicine market was valued at USD 118 billion in 2025. The market is projected to grow from USD 131.6 billion in 2026 to USD 277.8 billion by 2034, exhibiting a compound annual growth rate of 9.79% during the forecast period. Contrive Datum Insights presents this information in its report titled "Precision Medicine Market Size, Share & Industry Analysis, By Technology (Gene Sequencing, Precision Molecular Diagnostics, Bioinformatics, Drug Discovery, Big Data Analytics), Application (Oncology, Central Nervous System, Hematology, Respiratory, Immunology, Others), End user (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), Product & service (Diagnostics, Therapeutics, Precision Medicine Software & Services), Sample type (Blood-Based, Tissue-Based, Saliva & Other Biofluids), and Regional Forecast, 2026-2034".
Precision medicine covers the diagnostic tests, genomic and molecular profiling technologies, and biomarker-guided therapeutics used to tailor prevention, diagnosis and treatment decisions to an individual patient's genetic and molecular profile. It spans gene sequencing platforms, bioinformatics and data-analytics software, companion and complementary diagnostics, and the targeted drugs whose prescribing depends on a qualifying test result. Buyers include hospitals and reference laboratories that order and process testing, pharmaceutical and biotechnology companies that co-develop diagnostics alongside a therapy, and academic and research institutes that use the same platforms for discovery work.
Expanding companion-diagnostic approvals in oncology
Expanding companion-diagnostic approvals in oncology is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 9.79% a year, the technology lines exposed to it move fastest: Big Data Analytics compounds at 14.8%, taking its share of revenue from 8% to 12% and its value from USD 9.44 billion to USD 33.34 billion.
On the upside, the study's bull case assumes bull case assumes companion-diagnostic approvals and reimbursement coverage expand faster than modeled, pulling adoption forward across major markets, which would take 2034 revenue to USD 311.14 billion against the USD 277.8 billion base case.
On the downside, bear case assumes reimbursement expansion and sequencing-cost declines slow relative to the base case, delaying adoption in mid-sized markets, which would hold 2034 revenue to USD 244.46 billion. Precision Molecular Diagnostics, which carries 24% of 2025 revenue, already grows at only 8.72% against the market's 9.79%, so the largest part of the base is also its slowest.
Gene Sequencing Scale Against Big Data Analytics Momentum
Two positions matter, and they are set by technology. Gene Sequencing carries 28% of 2025 revenue (USD 33.04 billion) and is still the largest line in 2034 at 30%, hard to take from an incumbent. Big Data Analytics, at 14.8%, is where the USD 118 billion base is redistributed. The two demand different capabilities.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Application | Oncology | 45% · USD 53.1 billion | Immunology 12.23% |
| End user | Hospitals & Clinics | 30% · USD 35.4 billion | Pharmaceutical & Biotechnology Companies 11.04% |
| Product & service | Diagnostics | 48% · USD 56.64 billion | Precision Medicine Software & Services 14.17% |
| Sample type | Blood-Based | 52% · USD 61.36 billion | Saliva & Other Biofluids 11.52% |
- Regionally, the lead sits with North America: 42% of 2025 global revenue, USD 49.56 billion rising to USD 105.56 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 23% in 2025 to 28% in 2034, with revenue growing from USD 27.14 billion to USD 77.78 billion.
- At 5% of 2025 revenue and 5.5% by 2034, Middle East and Africa is the smallest region throughout.
- Gene Sequencing was the leading technology line in 2025, taking 28% of revenue at USD 33.04 billion.
- The fastest technology line is Big Data Analytics, forecast to compound at 14.8% through the period.
- The United States is the largest single country market at USD 42.13 billion in 2025, 35.7% of global revenue.
The study covers five axes, by technology, and by application, end user, product & service and sample type, reporting revenue and a growth rate for every line in every year from 2020 to 2034, with bear, base and bull scenarios on the headline total at USD 244.46 billion and USD 311.14 billion by 2034. Country-level detail is given for all five regions, together with the competitive landscape and the research methodology. Delivered as a PDF; request a free sample to review it.